EP300 and prostate carcinoma: The combination of I-CBP112 and A-485, targeting distinct parts of CBP/EP300—the bromodomain and histone acetyltransferase domain, respectively—arrested the proliferation of the prostate cancer cells as well as suppressed androgen-dependent and pro-oncogenic prostate genes, such as KLK3 (PSA) and c-Myc, which was followed by a strong reduction in p300 chromatin occupancy at their gene promoters [9].